Samsung BioLogics Signs 350.8 Billion Won Contract with European Pharma Firm, Cumulative Orders Reach $21.9 Billion

Contract Period Through 2033

Client and Product Names Undisclosed

Samsung BioLogics has signed a contract worth approximately 350 billion won for biopharmaceutical contract manufacturing (CMO) with a Europe-based pharmaceutical company. Moving forward, the company aims to strengthen partnerships with potential clients through its “three pillars of expansion” strategy by enhancing production capacity, portfolio, and global geographical presence.

A view of Samsung BioLogics Plant 4 in Songdo, Yeonsu-gu, Incheon. Samsung BioLogics

On September 10, Samsung BioLogics announced in a regulatory filing that it had secured a new CMO contract with a European pharmaceutical company valued at USD 262,182,000 (approximately 350.8 billion won). The contract period runs until December 31, 2033. Under the confidentiality agreement, the client and product names were not disclosed.

With this contract, Samsung BioLogics’ cumulative order intake since its establishment has reached USD 21.9 billion. The company has announced a total of six contract disclosures this year. Samsung BioLogics emphasized the significance of securing a long-term contract—with production and supply continuing through 2033—amid global economic uncertainties and intensifying competition in the contract development and manufacturing organization (CDMO) market. The company explained that this contract would allow it to secure a stable order backlog, thereby reinforcing its medium- to long-term revenue base.

The three-pillar strategy to expand production capacity, business portfolio, and overseas bases is also expected to gain further traction. In April last year, Samsung BioLogics began operation of its fifth plant with a capacity of 180,000 liters, and in March this year, it acquired a plant in Rockville, USA, with a capacity of 60,000 liters. As a result, the company’s total production capacity has grown to 845,000 liters. In addition, Samsung BioLogics plans to sequentially construct Plants 6 through 8 at its second bio campus in Songdo, Incheon, bringing total production capacity to 1,385,000 liters.

The company is also broadening its business scope, which was previously focused on antibody drugs. In addition to its existing antibody and messenger RNA (mRNA) pharmaceuticals, it has established dedicated antibody-drug conjugate (ADC) production facilities. In July this year, Samsung BioLogics announced its planned acquisition of PolyPeptide Group, signaling an entry into the peptide CDMO market.

The company is also strengthening its global sales network. In the third quarter of this year, it plans to open a European sales office in the Netherlands, establishing a business hub in another major global biopharmaceutical market following the United States and Japan. In terms of quality competitiveness, Samsung BioLogics achieved a 99% batch (manufacturing unit) success rate last year. As of September 2026, the company has accumulated 464 global regulatory manufacturing approvals.

A Samsung BioLogics representative commented, “We will focus our capabilities on attracting new clients and expanding contracts with existing clients in response to the increasing global demand for biopharmaceuticals and diversification of the supply chain.”

This content was produced with the assistance of AI translation services.